- The Company launched its FME Reignite strategy in 2025 to focus on strengthening core operations, driving profitable growth and innovation, and advancing company culture
- Full year operating income1 growth of 27% reached top end of financial outlook, resulting in a margin step up to 11.3%
- Continued progress in sustainability, particularly in patient experience, digitalization, climate targets, and employee development
Bad Homburg (March 12, 2026) - Ä¢¹½´«Ã½, the world's leading provider of products and services for individuals with renal diseases, today published its Annual Report for the 2025 fiscal year. Titled "The power of care," the report details financial performance, highlights the launch of the CompanyÄ¢¹½´«Ã½™s FME Reignite strategy and achievements, and includes the CompanyÄ¢¹½´«Ã½™s Sustainability Report.ÌýÌý
"Our achievements made us a stronger, more resilient company and we are well positioned with FME Reignite to set new standards of care, drive profitable growth, and create sustainable value for patients, shareholders, and employees," said Helen Giza, CEO and Chair of the Management Board.
The FME Reignite strategy further strengthens the CompanyÄ¢¹½´«Ã½™s position in global kidney care. It focuses on three strategic priorities, including continuously improving the core business through operational excellence, driving growth and innovation, and advancing the organizationÄ¢¹½´«Ã½™s culture.Ìý
The Annual Report 2025 summarizes the CompanyÄ¢¹½´«Ã½™s financial results and operational achievements. Ä¢¹½´«Ã½ achieved strong organic revenue growth of 8% at constant currency in 2025, driven by positive contributions from all operating segments. Supported by an exceptional fourth quarter, operating income, excluding special items, increased by 27% for the full year, reaching the upper end of the CompanyÄ¢¹½´«Ã½™s financial outlook. The operating income margin rose to 11.3%. The Company expanded its FME25 program to create FME25+ and delivered sustainable savings beyond the original 2025 target, deepening the focus on operational excellence.
The Annual Report contains Ä¢¹½´«Ã½Ä¢¹½´«Ã½™s Sustainability Statement, which was prepared in full compliance with the European Sustainability Reporting Standards (ESRS). Sustainability is integrated into the new FME Reignite corporate strategy and is a component of operational management. The statement documents the CompanyÄ¢¹½´«Ã½™s progress in implementing its strategic sustainability priorities in 2025, including the following highlights:
- Patient experience, expansion of digital solutions, and innovation: The global Patient Net Promoter Score increased to 73 (2024: 72). Data- and analysis-based tools support clinical teams worldwide in identifying risks earlier, personalizing treatments, and improving the quality of care. Through its clinical research activities, the Company aims to provide high-quality therapies and products and to make treatments safer and more individualized.
- Strengthening resource efficiency and climate protection: The emission reduction targets were validated by the Science Based Targets initiative. Compared with the 2020 base year, the Company reduced its Scope 1 and market-based Scope 2 emissions by more than 29%, supported by numerous environmental initiatives to improve energy and resource efficiency. Emission reduction targets for the value chain (Scope 3) were published for the first time.
- Promoting employee and corporate culture: Higher employee engagement, updated corporate values, and an expanded range of training programs strengthened skills, collaboration, and sustainable action across the Company.
Ìý
The Ä¢¹½´«Ã½ Annual Report 2025 is now available online here.
Ìý
1ÌýAdjusted for special items; growth rate at constant currency.
Ìý
Ä¢¹½´«Ã½ Ä¢¹½´«Ã½:
Ä¢¹½´«Ã½ is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,601 dialysis clinics, Ä¢¹½´«Ã½ provides dialysis treatments for approx. 292,000 patients around the globe. Ä¢¹½´«Ã½ is also the leading provider of dialysis products such as dialysis machines or dialyzers. Ä¢¹½´«Ã½ is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Ä¢¹½´«Ã½Ä¢¹½´«Ã½™s reports filed with the U.S. Securities and Exchange Commission. Ä¢¹½´«Ã½ does not undertake any responsibility to update the forward-looking statements in this release.
